Malaria parasite liver stages render host hepatocytes susceptible to mitochondria-initiated apoptosis

A Kaushansky*1, PG Metzger1, AN Douglass1, SA Mikolajczak1, V Lakshmanan1, HS Kain1 and SHI Kappe*1,2

Intracellular eukaryotic parasites and their host cells constitute complex, coevolved cellular interaction systems that frequently cause disease. Among them, *Plasmodium* parasites cause a significant health burden in humans, killing up to one million people annually. To succeed in the mammalian host after transmission by mosquitoes, *Plasmodium* parasites must complete intracellular replication within hepatocytes and then release new infectious forms into the blood. Using *Plasmodium yoelii* rodent malaria parasites, we show that some liver stage (LS)-infected hepatocytes undergo apoptosis without external triggers, but the majority of infected cells do not, and can also resist Fas-mediated apoptosis. In contrast, apoptosis is dramatically increased in hepatocytes infected with attenuated parasites. Furthermore, we find that blocking total or mitochondria-initiated host cell apoptosis increases LS parasite burden in mice, suggesting that an anti-apoptotic host environment fosters parasite survival. Strikingly, although LS infection confers strong resistance to extrinsic host hepatocyte apoptosis, infected hepatocytes lose their ability to resist apoptosis when anti-apoptotic mitochondrial proteins are inhibited. This is demonstrated by our finding that B-cell lymphoma 2 family inhibitors preferentially induce apoptosis in LS-infected hepatocytes and significantly reduce LS parasite burden in mice. Thus, targeting critical points of susceptibility in the LS-infected host cell might provide new avenues for malaria prophylaxis.

Results

We developed a system to quantitatively compare rates of apoptosis in LS infected and uninfected cells in the same culture by building on previous work utilizing flow cytometry to monitor infection rates.8 *Plasmodium yoelii*-infected Hepa 1–6 cell cultures were stained with two antibodies, one specific to circumsporozoite protein (CSP) (Figure 1a; Supplementary Figure 1) and a second that recognizes cleaved forms of caspase-3, a committed step in apoptosis (Figure 1b; Supplementary Figure 1). To ensure that caspase-3 signal was specific, extrinsic apoptotic signaling was triggered by

---

1Seattle Biomedical Research Institute, Seattle, WA, USA and 2Department of Global Health, University of Washington, Seattle, WA, USA

*Corresponding author: A Kaushansky or SHI Kappe, Malaria Program, Seattle Biomedical Research Institute, 307 Westlake Avenue North Suite 500, Seattle, WA 98109, USA; Tel.: +1 206 256 7216/7205; Fax: +1 206 256 7229; E-mail: alexis.kaushansky@seattlebiomed.org or stefan.kappe@seattlebiomed.org

Keywords: *Plasmodium*; liver stage; apoptosis; cellular signaling

Abbreviations: LS, liver stage; CSP, circumsporozoite protein; PVM, parasitophorous vacuole membrane; Bcl-2, B-cell lymphoma 2
treated Hepa1-6 cells with a Fas-activating antibody (Jo-2). We observed significantly elevated levels of apoptosis both 6 and 24 h following treatment with Jo-2 (Figure 1b). This demonstrates that Hepa 1–6 cells respond to Fas activation, and that monitoring caspase-3 cleavage in these cells unambiguously marks apoptosis.

A subset of LS-infected hepatocytes undergoes apoptosis. Surprisingly, untreated LS-infected cells more frequently exhibited elevated levels of apoptosis compared with untreated, uninfected cells 24 h after infection (Figure 1c; Supplementary Figure 1). This suggests that there is a subset of LS parasites that either cannot withstand the host defenses that trigger hepatocyte death or actively initiates apoptosis in their host cell. As hepatoma cells typically respond to apoptotic stimuli in different ways than primary hepatocytes, we tested the effect of host cell apoptosis on LS infection in vitro. BALB/cJ mice were treated with 20 mg/kg Q-VD-OPh beginning 1 h before infection, and then once daily. Mice were infected with 100,000 P. yoelli sporozoites. LS burden was measured 42–44 h after infection by quantitative PCR. Q-VD-OPh-treated mice have significantly higher LS burden than untreated mice. (e) Parasites treated with Q-VD-OPh or control were measured 42 h after infection. There is not a significant difference in the size of parasites, indicating that Q-VD-OPh-treated mice harbor more parasites, not similar numbers of larger parasites of LS burden observed was not due to increased growth but instead due to greater numbers of developing LS parasites. Taken together, these data suggest that under normal infection conditions in vivo, a subset of LS-infected hepatocytes die by caspase-dependent mechanisms without extrinsic pro-apoptotic stimuli. When host cell death is artificially blocked, these infected cells survive and allow parasites to develop.

Lack of a PVM induces apoptosis in LS-infected cells. It remains unknown whether impaired functions or fitness of the parasite could result in loss of apoptotic resistance in the infected host cell. It has been previously demonstrated that attenuated parasites that cannot complete LS development elicit apoptosis in infected hepatoma cells. When a viable malaria parasite productively invades a hepatocyte, it surrounds itself with a membrane of hepatocyte origin, called the PVM, which is subsequently modified by the LS parasite. This membrane serves as a critical interface between the parasite and its hepatocyte host. We hypothesized that the PVM might have a role in mediating resistance to host cell apoptosis after infection. We tested this by using transgenic parasites and markers that delineate parasites...
that have invaded with an intact PVM and those that reside inside the hepatocyte without a PVM.

Wild-type sporozoites can invade hepatocytes while forming a PVM (leading to productive infection) or enter by cell traversal, which is mediated by membrane wounding and does not form a PVM. 

13 Attenuated parasites that lack the 6-cys proteins P52 and P36 (p52(−)/p36(−)) enter hepatocytes but cannot form or maintain a PVM (Figure 2a). In contrast, parasites that lack the traversal protein SPECT2 can invade hepatocytes only during PVM formation (Supplementary Figure 2). Strikingly, when we infected cells with P. yoelii p52(−)/p36(−) parasites, we observed highly elevated levels of apoptosis in infected hepatocytes (Figure 2b) within 3 h of infection, which was not observed in P. yoelii wild-type-infected cells, suggesting that wild-type parasites have more robust control over their host cell. Furthermore, P. yoelii spect2(−) parasite-infected cells did not show substantial levels of apoptosis, even after 24 h when wild-type parasite-infected cells undergo significant apoptosis (Figure 2c). Because p52(−)/p36(−) parasites arrest soon after infection, and infected cells do not survive, we could not monitor apoptosis in p52(−)/p36(−) parasite-infected hepatocytes later during infection.

If wild-type parasite-infected hepatocytes remain unwounded, parasite entry must have occurred during the formation of a PVM (Figure 2d). Therefore, we marked wounded cells by including fluorescently labeled dextran in the hepatocyte culture media before parasite addition. As before, we marked the presence of intracellular parasites using an antibody against CSP. After 24 h, we observed that parasite-harboring host cells that had been wounded exhibited higher levels of apoptosis than parasite-harboring hepatocyte that were not wounded (Figure 2e). This suggests that wild-type parasites that enter a hepatocyte without PVM formation are more likely to induce apoptosis in their host cell than parasites that invade with forming a PVM. The rate of apoptosis is higher in wounded cells containing parasites than in wounded cells without parasites, suggesting that cell wounding itself does not initiate substantial levels of apoptosis. Rather, the presence of the LS parasite not ensconced by a PVM results in host cell death. Taken together, these observations indicate that the LS PVM has an important role in protecting the infected host hepatocyte from apoptosis.

**Mitochondrial signaling has a critical role in regulating host hepatocyte apoptosis during LS infection.** Hepato-
cytes are type II cells and thus preferentially utilize mitochondrial signaling to facilitate both intrinsic and extrinsic apoptosis. Mitochondrial control of apoptosis is tightly regulated by a family of BH3-domain-containing proteins, which participate in direct protein–protein interactions to provide cellular resistance or sensitivity to apoptosis (Figure 4a). 10 Cleavage of Bid (to produce t-Bid) is required for initiation of mitochondrial apoptosis; therefore, elimination of Bid generally inhibits intrinsic and extrinsic apoptosis in hepatocytes. To determine if the mitochondrial pathway is responsible for mediating apoptosis in the population of LS-infected cells that cannot survive under basal conditions, we compared total P. yoelii LS burden in wild-type and Bid(−/−) mice. We found that Bid(−/−) mice had substantially elevated LS parasite burden (Figure 4b) similar to the increase observed when inhibiting all apoptosis with Q-VD-OPh pan-
caspase inhibitor treatment (Figure 2c). The data show that the mitochondrial apoptotic cascade has a significant role in eliminating LS-infected hepatocytes in vivo. Thus, mito-
cochondrial apoptosis is a key node of susceptibility for LS-infected hepatocytes. Consequently, infected hepatocytes could be hypersusceptible to the activation of the mitochondrial apoptotic pathway.

**Apoptotic susceptibility of LS-infected hepatocytes is enhanced by targeting key mitochondrial signaling nodes.** B-cell lymphoma 2 (Bcl-2) family members are critical for blocking pro-apoptotic signaling in the mitochondria, and inhibition of these proteins leads to mitochondria-
driven apoptosis. We utilized the well-characterized Bcl-2 family inhibitor, ABT-737, 19 and found that increasing concentrations of ABT-737 ranging from 50 to 200 nM (Figure 5a) increased levels of apoptosis in uninfected Hepa 1–6 cells. To exclude any direct effects on the parasite, we tested ABT-737 on Plasmodium falciparum blood stages, and found that it had no substantial effect at even the highest concentration used (Figure 5b). We then asked if boosting pro-apoptotic signaling in the host cell mitochondria using ABT-737 had a substantial impact on LS-infected host cell survival. Indeed, LS burden was significantly decreased when infected Hepa 1–6 cultures were treated with ABT-737 ranging in concentration from 50 to 200 nM (Figure 5c). Importantly, ABT-737 was able to significantly reduce LS parasite burden with doses much lower than those used to treat cancer cells. 18,20 Strikingly, we found that at lower concentrations (50 and 75 nM) LS-infected cells were heavily
sensitized to ABT-737, exhibiting far higher levels of apoptosis than uninfected cells (Figure 5d). Thus, enabling mitochondrial apoptosis is effective at preferentially eliminating infected hepatocytes. Interestingly, \( \text{Spect2}(-)/\text{C0} \) infected hepatocytes, as well as wild-type-infected cells with or without an intact PVM, all exhibited this sensitivity, suggesting that Bcl-2 family inhibition overwrites any anti-apoptotic signals initiated by LS parasites (Supplementary Figure 3).

We next investigated if another Bcl-2 family inhibitor could prove as effective at clearing parasite-infected hepatocytes while having little impact on uninfected hepatocytes. We chose to utilize obatoclax mesylate, a pan-Bcl-2 family inhibitor with low levels of toxicity, which is orally bioavailable.\(^21,22\) We found that obatoclax induces a measurable but substantially lower level of apoptosis in uninfected Hepa1-6 cells when compared with ABT-737 (Figure 5e), and, like ABT-737, it did not directly kill blood stage parasites at the concentrations used (Figure 5f). Yet, obatoclax reduced the number of LS-infected cells \textit{in vitro} by >70% (Figure 5g), but at the same concentrations it had limited effects on apoptosis in uninfected cells (Figure 5h).
Finally, to extend the findings to an animal model, we treated BALB/cJ mice with 5 mg/kg obatoclax or vehicle alone (9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose), infected the mice with 100,000 *P. yoelii* sporozoites, and measured LS burden after 42 h. Infected mice treated with obatoclax had dramatically lower LS parasite burden when compared with vehicle-treated infected mice (Figure 5i). Obatoclax treatment was well tolerated, and mice appeared healthy after 72 h of treatment. The data demonstrate that sensitizing LS-infected hepatocytes to apoptosis can substantially reduce parasite burden in the liver.

**Discussion**

Interactions between the malaria parasite LS and its hepatocyte host are complex from the time of sporozoite invasion until the ultimate release of first-generation red blood cell-infectious forms. The parasite has evolved to control and exploit its host cell, thereby ensuring successful transition to blood infection and transmission. The PVM constitutes the principal host–parasite interface and is critical to mediate this exploitative relationship. We demonstrate that the ability of the LS to form a PVM can alter the balance between survival and apoptosis of the infected hepatocyte. It has been previously
shown by van Dijk et al.\textsuperscript{10} that \textit{P. berghei} \textit{p52(−)} parasites induce apoptosis in their host hepatocyte soon after infection. It remains unclear if these parasites are able to initially form or partially form a PVM during invasion, and thus it remains to be seen if parasites, which die within their host hepatocyte, also induce apoptosis if a PVM is formed before developmental arrest. It also remains unknown whether loss of PVM integrity simply exposes the hepatocyte to pro-apoptotic attributes of...
the parasite or if aspects of the PVM are actively engaged in modulating hepatocyte apoptosis.

The premature death of the infected hepatocyte not only ends the life of the LS contained within but also affects the surrounding liver tissue and generates immune responses that can have an impact on subsequent infections. A pro-survival response in the infected cell allows the parasite to thrive and remain immunologically inert. Although it is tempting to characterize the signaling in the infected hepatocyte as strictly pro-survival or pro-death, the data presented here suggest a more complex dynamic relationship between the LS parasite and its host hepatocyte than previously appreciated. The interaction between a subset of parasites and their host hepatocyte results in infected host cell death; however, the majority of parasites in the population impose survival of the infected hepatocytes, and these also actively resist Fas-mediated apoptosis. Interestingly, LS-infected hepatocytes are unable to resist mitochondrial-driven apoptotic stimuli. Thus, mitochondrial signaling in the infected hepatocyte represents a key node of susceptibility for LS parasite infection.

It has been previously demonstrated that *P. berghei* LS-infected hepatoma cells can resist apoptosis that is initiated by cycloheximide and tumor necrosis factor in combination, or t-butyl-hydroperoxide. These stimuli that are not physiologically relevant or present in the resting liver. It has also been shown that infected host cells undergo non-apoptotic cell death at the end of LS development, presumably to foster release of infectious forms into the blood stream. Here we demonstrate for the first time that infected hepatocytes respond differently to diverse apoptotic stimuli. These findings highlight the importance of analyzing LS-infected cells not strictly on a population level, but also addressing the variation within the population. Moving forward, single-cell analyses will be critical to a more comprehensive understanding of the intricate interplay of LS parasites and their hepatocyte hosts.

The complex perturbations caused by *Plasmodium* LS infection are multifaceted stimuli for the infected hepatocyte. Although it is tempting to simplify the hepatocyte response to LS infection as an additive response to the collection of stimuli present, work in the last decade has demonstrated that combinations of cellular stimuli do not always behave as a simple sum of their parts. For instance, cells that proliferate in response to growth factor, or undergo low-level apoptosis in response to tumor necrosis factor, undergo substantially elevated levels of apoptosis when treated with growth factor and tumor necrosis factor in combination. In cancer treatment, the role of mitochondrial apoptotic signaling in combination with other cellular events is already being translated to the clinic; drugs that target the Bcl-2 pathways are being tested as sensitization agents in combination with more traditional chemotherapy. Additional insight regarding the wiring of signaling networks in hepatocytes will provide a framework to more fully understand the nuances of the interaction between the host hepatocyte and LS parasite, and also additional insights into the optimal points of intervention.

Although there is no evidence that LS parasites transform their host cell, recent evidence suggests that *P. yoelii*-infected hepatocytes are not entirely distinct from cancer cells. We have demonstrated that averaged over the population, LS-infected hepatocytes exhibited elevated levels of proteins regulating cell cycle progression and survival, and diminished levels of proteins involved in autophagic and apoptotic signaling. Here we demonstrate that although many parasites successfully evade hepatocyte defenses and protect their host cell against extrinsic apoptosis, a subset of LS parasites engage the apoptotic machinery and are cleared from the liver, along with their host hepatocytes. In addition, our previous work demonstrated that mitochondrial proteins Bcl-2 and Bad were skewed toward anti-apoptotic signaling; here we show that reversing this perturbation by inhibiting the Bcl-2 family overcomes the apoptotic block placed by the parasite and thus eliminates infected cells. Interestingly, the parasite-driven modulation of another hepatocyte protein, p53, exhibits a similar pattern: the parasite actively suppresses hepatocyte p53, but when this suppression is reversed with a small molecule, infected cells are eliminated. As additional data are generated that fully characterize the host cell-signaling milieu in which the LS parasite thrives, a more comprehensive understanding of the points of susceptibility will emerge. It is enticing to ask if combinations of host-targeted drugs, aimed at both activating p53 and mitochondrial apoptosis, could lead to the complete elimination of LS infected cells, and thus the onset of clinical malaria.

The efficacy of host-based therapeutics aimed at the mitochondrial apoptotic cascade might be restricted to hepatotropic pathogens, or might even be exclusive to *Plasmodium* species. The hepatocyte microenvironment that houses the malaria LS parasite is unique in many ways and presents a finite set of challenges for the developing LS to overcome. LS parasites can resist Fas stimulation but cannot resist apoptotic insults initiated in the mitochondria. By comparison, *Toxoplasma* species, unlike *Plasmodium*, invade a variety of cell types, and thus come in contact with...
a greater diversity of challenges. It has been demonstrated that many components of the mitochondrial apoptotic signaling network are strongly inhibited in Toxoplasma-infected cells, suggesting that these parasites, unlike Plasmodium, might be able to resist even mitochondrial-targeted insults. It remains an unanswered question if more host cell-promiscuous parasite species have the capacity to resist a wider variety of apoptotic stimuli.

Parasite evolution has been a challenge for combating malaria, as rapidly replicating parasites frequently become drug resistant. Targeting critical host signaling node(s) could provide protection against the development of drug resistance. However, to date, little attention has been given to develop host-based prophylaxis aimed at selectively eliciting apoptosis in infected cells, perhaps because of early studies demonstrating that infected cells could resist apoptosis. Here we provide evidence that initiating apoptosis by targeting the mitochondrial cascade preferentially targets Plasmodium-infected hepatocytes. These findings argue for further investigation into, and broadening the targets of, host-based strategies to prevent malaria.

Materials and methods

Cell lines and culture. Hepa 1–6 Cells were a gift from Ana Rodriguez (NYU). Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) complete media (Cellgro, Manassas, VA, USA), supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA), 100 U/ml penicillin (Cellgro), 100 μg/ml streptomycin (Cellgro), 2.5 μg/ml fungzone (HyClone/Thermo Fisher, Waltham, MA, USA), and 5 μg/ml gentamycin (BioWhittaker/Lonza, Basel, Switzerland), and split 1–2 times weekly. Where indicated, cells were treated with ABT-737 (SelleckChem, Houston, TX, USA) and obatoclax mesylate (SelleckChem) at indicated concentrations. Both molecules were dissolved in DMSO for cell culture experiments.

Mosquito rearing and sporozoite production. For P. yoelii sporozoite production, female 6–8-week-old Swiss Webster mice (Harlan, Indianapolis, IN, USA) were injected with blood stage parasites and harvested 29–32 days later. Sporozoites were centrifuged for 3 min at 515 g in a hanging-bucket centrifuge to aid in sporozoite invasion. After 90 min, we removed media that contained sporozoites that had not invaded and/or developed in hepatoma cells were distinguished by U94 non-circumferential staining and morphology.

Quantification of LS parasites after Fas, ABT-737, or obatoclax treatment by manual counting. In all, 5 × 10⁵ Hepa 1-6 cells were grown in DMEM complete medium in each well of an eight-well Permanox slide. For Fas experiments, cells were treated with Jo-2 (BD Biosciences, San Jose, CA, USA) or IgG control for 24 h. For ABT-737 and obatoclax experiments, cells were treated with DMSO alone or drug for 24 h as described above. Cells were infected with 5 × 10⁴ P. yoelii sporozoites. Slides were centrifuged for 3 min at 515 g in a hanging-bucket centrifuge to aid in sporozoite invasion. After 90 min, we removed media that contained sporozoites that had not invaded and/or developed in hepatoma cells were distinguished by U94 non-circumferential staining and morphology. All LSs in each well were counted, and each assay was performed in biological triplicate.

Quantification of LS parasites by FACs. Cells were cultured as described above. In all, 3 × 10⁵ or 6 × 10⁵ cells were plated in each well of a 24-well or 12-well plate and infected with 10⁵ or 2 × 10⁵ P. yoelii sporozoites, respectively. Cells were treated with or without ABT-737 or obatoclax, as described above. At the desired time point, cells were trypsinized and then fixed with Perm/Fix buffer (BD Biosciences). Cells were blocked in Perm/Wash buffer (BD Biosciences) supplemented with 2% BSA. Additional staining steps were performed in Perm/Wash buffer alone. We stained cells using the monoclonal antibody to CSP conjugated to AlexaFluor-488 or AlexaFluor-647, as well as an antibody to cleaved caspase-3 conjugated to phycoerythrin (PE; Cell Signaling Technology, Danvers, MA, USA). All experimental conditions were tested in biological triplicate. All data are representative of three independent experiments.
the purified DNA from each mouse was amplified according to the Jax genotyping specifications; the common reverse primer (oIMR9558; 5′-CCGAATGTTCCCA-TAAGAG-3′), wild-type forward primer (oIMR9559; 5′-GAGTTGACACACATCATC-3′), and mutant forward primer (oIMR960; 5′-GCTGACTCTCCATCTGACGCTCC-3′) were used to identify the wild-type (124 bp) and PGK-neo cassette (350 bp) products.

In vivo obatoclax experiments. Eighty BALB/cj mice (Jackson Laboratory, Bar Harbor, ME, USA) were treated with either vehicle control or 5 mg/kg of obatoclax by oral gavage once daily for 3 days. On the second day of treatment, mice were injected with 10^5 P. yoelli sporozoites. Livers were excised from mice at 44 h after infection. Animal handling was conducted according to the Institutional Animal Care and Use Committee-approved protocols.

In vivo Q-VD-OPh experiments. Thirty BALB/cj mice (Jackson) were treated with either vehicle control or 20 mg/kg of Q-VD-OPh (SM Biochemicals, Laboratory, Bar Harbor, ME, USA) were treated with either vehicle control or 20 mg/kg of Q-VD-OPh (SM Biochemicals, Laboratory, Bar Harbor, ME, USA) once daily for 3 days. On the second day of treatment, mice were injected with 10^5 P. yoelli sporozoites. Livers were excised from mice at 44 h after infection. Animal handling was conducted according to the Institutional Animal Care and Use Committee-approved protocols.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

We are grateful to William W. Betz and Jen C.C. Hume for mosquito and sporozoite production. We thank Hieu Nguyen for technical assistance with FACS and Marian Abdullahi for excellent technical assistance with in vitro experiments. We thank Roberto Guirnalda, Lynett Robertson and Seattle Biomedical Research Institute vivarium staff for their work with mice. AK is a recipient of a NRSA Ruth L. Kirschstein National Research Service Award (F32 AI091129), which has partially funded this work. This work has also been partially funded by 1R01GM101183-01A1 to SHIK.

Author contributions

AK and SHIK designed the research. AK, PGM, AND, SAM, VL, and HSK performed the experiments. AK, PGM, AND and SHIK analyzed the data. AK and SHIK wrote the paper with input from all others.

1. Mackinnon MJ, Marsh K. The selection landscape of malaria parasites. Science 2010; 328: 866–871.
2. Fidock DA. Drug discovery: priming the antimalarial pipeline. Nature 2010; 465: 297–298.
3. Kappe SH, Vaughan AM, Boddley JA, Cowman AF. That was then but this is now: malaria research in the time of an eradication agenda. Science 2010; 328: 862–866.
4. van de Sand C, Horstmann S, Schmidt A, Sturm A, Bolte S, Krueger A et al. HGF/MET signaling protects in vitro hepatitis C virus infected cells from apoptosis. Cell Microbiol 2005; 7: 603–609.
5. Yin XM, Wang K, Gross A, Zhao Y, Zinkiel S, Klocke B et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886–891.
6. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsokopoulou V, Ross AJ et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727–730.
7. Kaushansky A, Rezakhani N, Mann H, Kappe SH. Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites. Mol Biochem Parasitol 2012; 183: 100–103.
8. Prudencio M, Mota MM, Mendes AM. A toolbox to study liver stage malaria. Trends Parasitol 2011; 27: 565–574.
9. van Dijk MR, Doorduin B, Franke-Fayard B, Heussler V, van Dorenen MW, van Schaijk B et al. Genetically attenuated, P65-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 2005; 102: 12194–12199.
10. Mueller AK, Camargo N, Kaiser K, Andorfer C, Frevert U, Matsuhashi K et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 2005; 102: 3022–3027.
11. Mikolajczak SA, Jacobs-Lorena V, MacKellar DC, Camargo N, Kappe SH. L-FABP is a critical host factor for successful malaria liver stage development. Int J Parasitol 2007; 37: 483–489.
12. Mota MM, Pradel G, Vanderberg JP, Hafalla JC, Frevert U, Nussenzweig RS et al. Migration of Plasmodium sporozoites through cells before infection. Science 2001; 291: 141–144.
13. Mikolajczak SA, Jacobs-Lorena V, MacKellar DC, Nath A, Kappe SH. Plasmodium yoelli sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 2007; 75: 3758–3768.
14. Chirimu N, Mosconi AD, Qian Y, Qian R, Chen Y, Wilson JM. Fas-Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer. Hum Gene Ther 1999; 10: 259–265.
15. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl-inhibitor obatoclax (GX15-070) in multiple myeloma. Blood 2007; 109: 5430–5438.
16. O’Brien SM, Claxton DF, Cump M, Fader S, Kipps T, Keating MJ et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist and efficiently induces apoptosis via Bak/Bax independent pathways. Cancer Cell 2008; 10: 389–399.
17. Kline MP, Rajiumar SV, Timm MM, Kinling TR, Haug JL, Lust JA et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007; 21: 1549–1560.
18. Happo L, Strasser A, Cory S. BH3-only proteins in apoptosis at a glance. Cell 2005; 122: 1081–1087.
19. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax-independent pathways. Cancer Cell 2008; 10: 279–290.
20. Vaughan AM, Aly AS, Kappe SH. Malaria parasite pre-sporozoite stage inhibition: gliding and hiding. Cell Host Microbe 2008; 4: 209–218.
21. Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, Rennengeren AB et al. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 2006; 313: 1297–1299.
22. James KA, Albeck JG, Gaudet S, Sorger P, Kaufmann SH. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 2005; 310: 1650–1653.
23. Beyer EM, MacBeath G. Cross-talk between receptor tyrosine kinase and tumor necrosis factor-alpha signaling networks regulates apoptosis but not proliferation. Mol Cell Proteomics 2012; 11: M111 03292.
24. Hartman ML, Czyz M. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy. Anti-cancer Agents Med Chem 2012; 12: 966–981.
25. Kaushansky A, Ye AS, Austin LS, Mikolajczak SA, Vaughan AM, Camargo N et al. Suppression of host p53 is critical for Plasmodium liver-stage infection. Cell Rep 2013; 3: 630–637.
26. Mele R, Gomez Morales MA, Tosini F, Pozzo E. Cryptosporidium parvum at different developmental stages modulates host cell apoptosis in vitro. Infect Immun 2004; 72: 6601–6607.
27. Aoki M, Carl RC, Pellegrini AV, Tanos T, Guizadi NL, Coso OA et al. Different signaling pathways are involved in cardiomyocyte survival induced by a trypanosomatid glycoprotein. Microbes Infect 2006; 8: 1273–1313.
28. Guerignon J, Desaigue F, Tranchard F, Cayla X, Rebollo A, Bost PE et al. A PKA survival pathway inhibited by DPT-PKI, a new specific cell permeable PKA inhibitor, is induced by T. annulata in paralyzed B-lymphocytes. Apoptosis 2006; 11: 1253–1273.
29. Carmen JC, Hardi L, Sinai AP. Toxoplasma gondii inhibits ultraviolet light-induced apoptosis through multiple interactions with the mitochondrion-dependent programmed cell death pathway. Cell Microbio 2006; 8: 301–315.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/